The structural immunology of antibody protection against West Nile virus

Immunological Reviews

Volumn 225, Issue 1, 2008, Pages 212-225

  Diamond, Michael S ^a   Pierson, Theodore C ^b   Fremont, Daved H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Antibodies; Antigens peptides epitopes; Complement; Emerging infectious disease; Infectious diseases

Indexed keywords

EPITOPE; FC RECEPTOR; IMMUNOGLOBULIN FC FRAGMENT; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; NONSTRUCTURAL PROTEIN 1; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANTIBODY STRUCTURE; DRUG EFFICACY; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; VIRION; VIRUS INFECTION; VIRUS MORPHOLOGY; WEST NILE FLAVIVIRUS;

ANIMALS; ANTIBODIES, VIRAL; EPITOPES; HUMANS; VIRAL NONSTRUCTURAL PROTEINS; VIRAL PROTEINS; WEST NILE FEVER; WEST NILE VIRUS;

EID: 52049125010     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2008.00676.x     Document Type: Review

References (139)

1. Hayes EB, Komar N, Nasci RS, Montgomery SP, O'Leary DR, Campbell GL. Epidemiology and transmission dynamics of West Nile virus disease. Emerg Infect Dis 2005 11 : 1167 1173.
2. Sejvar JJ, et al. Neurologic manifestations and outcome of West Nile virus infection. JAMA 2003 290 : 511 515.
3. Lanciotti RS, et al. Complete genome sequences and phylogenetic analysis of West Nile virus strains isolated from the United States, Europe, and the Middle East. Virology 2002 298 : 96 105.
4. Beasley DW, Li L, Suderman MT, Barrett AD. Mouse neuroinvasive phenotype of West Nile virus strains varies depending upon virus genotype. Virology 2002 296 : 17 23.
5. Beasley DW, et al. Genome sequence and attenuating mutations in West Nile virus isolate from Mexico. Emerg Infect Dis 2004 10 : 2221 2224.
6. Brault AC, et al. A single positively selected West Nile viral mutation confers increased virogenesis in American crows. Nat Genet 2007 39 : 1162 1166.
7. Berthet FX, Zeller HG, Drouet MT, Rauzier J, Digoutte JP, Deubel V. Extensive nucleotide changes and deletions within the envelope glycoprotein gene of Euro-African West Nile viruses. J Gen Virol 1997 78 : 2293 2297.
8. Jupp PG. The ecology of West Nile virus in South Africa and the occurrence of outbreaks in humans. Ann NY Acad Sci 2001 951 : 143 152.
9. Petersen LR, Marfin AA, Gubler DJ. West Nile virus. JAMA 2003 290 : 524 528.
10. Deardorff E, et al. Introductions of West Nile virus strains to Mexico. Emerg Infect Dis 2006 12 : 314 318.
11. Komar N, Clark GG. West Nile virus activity in Latin America and the Caribbean. Rev Panam Salud Publica 2006 19 : 112 117.
12. Huhn GD, et al. The emergence of West Nile virus during a large outbreak in Illinois in 2002. Am J Trop Med Hyg 2005 72 : 768 776.
13. Davis LE, et al. West Nile virus neuroinvasive disease. Ann Neurol 2006 60 : 286 300.
14. Busch MP, et al. Screening the blood supply for West Nile virus RNA by nucleic acid amplification testing. N Engl J Med 2005 353 : 460 467.
15. Samuel MA, Diamond MS. Pathogenesis of West Nile virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion. J Virol 2006 80 : 9349 9360.
16. Brinton MA. The molecular biology of West Nile virus: a new invader of the western hemisphere. Annu Rev Microbiol 2002 56 : 371 402.
17. Diamond MS, Shrestha B, Marri A, Mahan D, Engle M. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol 2003 77 : 2578 2586.
18. Engle M, Diamond MS. Antibody prophylaxis and therapy against West Nile Virus infection in wild type and immunodeficient mice. J Virol 2003 77 : 12941 12949.
19. Ben-Nathan D, Lustig S, Tam G, Robinzon S, Segal S, Rager-Zisman B. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating west nile virus infection in mice. J Infect Dis 2003 188 : 5 12.
20. Oliphant T, et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 2005 11 : 522 530.
21. Oliphant T, et al. Determinants of West Nile virus envelope protein domains I and II antibody recognition and neutralization. J Virol 2006 80 : 12149 12159.
22. Gould LH, et al. Protective and therapeutic capacity of human single chain Fv-Fc fusion proteins against West Nile virus. J Virol 2005 79 : 14606 14613.
23. Throsby M, et al. Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile virus. J Virol 2006 80 : 6982 6992.
24. Tesh RB, Arroyo J, Travassos Da Rosa AP, Guzman H, Xiao SY, Monath TP. Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model. Emerg Infect Dis 2002 8 : 1392 1397.
25. Morrey JD, et al. Humanized monoclonal antibody against West Nile virus E protein administered after neuronal infection protects against lethal encephalitis in hamsters. J Infect Dis 2006 194 : 1300 1308.
26. Samuel MA, Wang H, Siddharthan V, Morrey JD, Diamond MS. Axonal transport mediates West Nile virus entry into the central nervous system and induces acute flaccid paralysis. Proc Natl Acad Sci USA 2007 104 : 17140 17145.
27. Chung KM, et al. Antibodies against West Nile virus non-structural (NS)-1 protein prevent lethal infection through Fc gamma receptor-dependent and independent mechanisms. J Virol 2006 80 : 1340 1351.
28. Johnston LJ, Halliday GM, King NJ. Phenotypic changes in Langerhans' cells after infection with arboviruses: a role in the immune response to epidermally acquired viral infection? J Virol 1996 70 : 4761 4766.
29. Johnston LJ, Halliday GM, King NJ. Langerhans cells migrate to local lymph nodes following cutaneous infection with an arbovirus. J Invest Dermatol 2000 114 : 560 568.
30. Byrne SN, Halliday GM, Johnston LJ, King NJ. Interleukin-1beta but not tumor necrosis factor is involved in West Nile virus-induced Langerhans cell migration from the skin in C57BL/6 mice. J Invest Dermatol 2001 117 : 702 709.
31. Daffis S, Samuel MA, Keller BC, Gale M Jr., Diamond MS. Cell-specific IRF-3 responses protect against West Nile virus infection by interferon-dependent and independent mechanisms. PLoS Pathog 2007 3 : e106.
32. Arjona A, et al. West Nile virus envelope protein inhibits dsRNA-induced innate immune responses. J Immunol 2007 179 : 8403 8409.
33. Silva MC, Guerrero-Plata A, Gilfoy FD, Garofalo RP, Mason PW. Differential activation of human monocyte-derived and plasmacytoid dendritic cells by West Nile virus generated in different host cells. J Virol 2007 81 : 13640 13648.
34. Bourne N, et al. Early production of type I interferon during West Nile virus infection: role for lymphoid tissues in IRF3-independent interferon production. J Virol 2007 81 : 9100 9108.
35. Fredericksen BL, Keller BC, Fornek J, Katze MG, Gale M Jr. Establishment and maintenance of the innate antiviral response to West Nile virus involves both RIG-I and MDA5 signaling through IPS-1. J Virol 2008 82 : 609 616.
36. Xiao SY, Guzman H, Zhang H, Travassos da Rosa AP, Tesh RB. West Nile virus infection in the golden hamster (Mesocricetus auratus): a model for West Nile encephalitis. Emerg Infect Dis 2001 7 : 714 721.
37. Chambers TJ, Diamond MS. Pathogenesis of flavivirus encephalitis. In : Chambers TJ, Monath TP, eds. The Flaviviruses: Current Molecular Aspects of Evolution, Biology, and Disease Prevention. London : Academic Press, 2003 : 273 342.
38. Shrestha B, Gottlieb DI, Diamond MS. Infection and injury of neurons by West Nile encephalitis virus. J Virol 2003 77 : 13203 13213.
39. Samuel MA, Morrey JD, Diamond MS. Caspase-3 dependent cell death of neurons contributes to the pathogenesis of West Nile virus encephalitis. J Virol 2007 81 : 2614 2623.
40. Samuel MA, Diamond MS. Type I IFN protects against lethal West Nile Virus infection by restricting cellular tropism and enhancing neuronal survival. J Virol 2005 79 : 13350 13361.
41. Diamond MS, Sitati E, Friend L, Shrestha B, Higgs S, Engle M. Induced IgM protects against lethal West Nile Virus infection. J Exp Med 2003 198 : 1 11.
42. Mehlhop E, Diamond MS. Protective immune responses against West Nile virus are primed by distinct complement activation pathways. J Exp Med 2006 203 : 1371 1381.
43. Mehlhop E, Whitby K, Oliphant T, Marri A, Engle M, Diamond MS. Complement activation is required for the induction of a protective antibody response against West Nile virus infection. J Virol 2005 79 : 7466 7477.
44. Wang T, Town T, Alexopoulou L, Anderson JF, Fikrig E, Flavell RA. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med 2004 10 : 1366 1373.
45. Arjona A, et al. Abrogation of macrophage migration inhibitory factor decreases West Nile virus lethality by limiting viral neuroinvasion. J Clin Invest 2007 117 : 3059 3066.
46. Hunsperger EA, Roehrig JT. Temporal analyses of the neuropathogenesis of a West Nile virus infection in mice. J Neurovirol 2006 12 : 129 139.
47. Samuel MA, et al. PKR and RNAse L contribute to protection against lethal West Nile virus infection by controlling early viral spread in the periphery and replication in neurons. J Virol 2006 80 : 7009 7019.
48. Scherbik SV, Paranjape JM, Stockman BM, Silverman RH, Brinton MA. RNase L plays a role in the antiviral response to West Nile virus. J Virol 2006 80 : 2987 2999.
49. Gilfoy FD, Mason PW. West Nile virus-induced IFN production is mediated by the double-stranded RNA-dependent protein kinase, PKR. J Virol 2007 81 : 11148 11158.
50. Keller BC, et al. Resistance to alpha/beta interferon is a determinant of West Nile virus replication fitness and virulence. J Virol 2006 80 : 9424 9434.
51. Anderson JF, Rahal JJ. Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro. Emerg Infect Dis 2002 8 : 107 108.
52. Lucas M, et al. Infection of mouse neurones by West Nile virus is modulated by the interferon-inducible 2′-5′ oligoadenylate synthetase 1b protein. Immunol Cell Biol 2003 81 : 230 236.
53. Fredericksen BL, Smith M, Katze MG, Shi PY, Gale M. The host response to West Nile virus infection limits spread through the activation of the interferon regulatory factor 3 pathway. J Virol 2004 78 : 7737 7747.
54. Liu WJ, Wang XJ, Mokhonov VV, Shi PY, Randall R, Khromykh AA. Inhibition of interferon signaling by the New York 99 strain and kunjin subtype of West Nile virus involves blockage of STAT1 and STAT2 activation by nonstructural proteins. J Virol 2005 79 : 1934 1942.
55. Wang T, et al. IFN-γ-producing γδ T cells help control murine West Nile virus infection. J Immunol 2003 171 : 2524 2531.
56. Shrestha B, et al. Gamma interferon plays a crucial early antiviral role in protection against West Nile virus infection. J Virol 2006 80 : 5338 5348.
57. Perelygin AA, Scherbik SV, Zhulin IB, Stockman BM, Li Y, Brinton MA. Positional cloning of the murine flavivirus resistance gene. Proc Natl Acad Sci USA 2002 99 : 9322 9327.
58. Mashimo T, et al. A nonsense mutation in the gene encoding 2′-5′-oligoadenylate synthetase/L1 isoform is associated with West Nile virus susceptibility in laboratory mice. Proc Natl Acad Sci USA 2002 99 : 11311 11316.
59. Shrestha B, Diamond MS. The role of CD8+ T cells in the control of West Nile virus infection. J Virol 2004 78 : 8312 8321.
60. Wang Y, Lobigs M, Lee E, Mullbacher A. CD8+ T cells mediate recovery and immunopathology in West Nile virus encephalitis. J Virol 2003 77 : 13323 13334.
61. Shrestha B, Samuel MA, Diamond MS. CD8+ T cells require perforin to clear West Nile virus from infected neurons. J Virol 2006 80 : 119 129.
62. Wang Y, Lobigs M, Lee E, Mullbacher A. Exocytosis and Fas mediated cytolytic mechanisms exert protection from West Nile virus induced encephalitis in mice. Immunol Cell Biol 2004 82 : 170 173.
63. Shrestha B, Diamond MS. Fas Ligand interactions contribute to CD8+ T cell-mediated control of West Nile virus infection in the central nervous system. J Virol 2007 81 : 11749 11757.
64. Mukhopadhyay S, Kuhn RJ, Rossmann MG. A structural perspective of the flavivirus life cycle. Nat Rev Microbiol 2005 3 : 13 22.
65. Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC. The envelope glycoprotein from tick-borne encephalitis virus at 2 Angstrom resolution. Nature 1995 375 : 291 298.
66. Modis Y, Ogata S, Clements D, Harrison SC. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci USA 2003 100 : 6986 6991.
67. Kanai R, et al. Crystal structure of West Nile virus envelope glycoprotein reveals viral surface epitopes. J Virol 2006 80 : 11000 11008.
68. Nybakken GE, Nelson CA, Chen BR, Diamond MS, Fremont DH. Crystal structure of the West Nile virus envelope glycoprotein. J Virol 2006 80 : 11467 11474.
69. Allison SL, Schalich J, Stiasny K, Mandl CW, Heinz FX. Mutational evidence for an internal fusion peptide in flavivirus envelope protein E. J Virol 2001 75 : 4268 4275.
70. Modis Y, Ogata S, Clements D, Harrison SC. Structure of the dengue virus envelope protein after membrane fusion. Nature 2004 427 : 313 319.
71. Bressanelli S, et al. Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation. EMBO J 2004 23 : 728 738.
72. Bhardwaj S, Holbrook M, Shope RE, Barrett AD, Watowich SJ. Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein. J Virol 2001 75 : 4002 4007.
73. Chu JJ, Rajamanonmani R, Li J, Bhuvanakantham R, Lescar J, Ng ML. Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoprotein. J Gen Virol 2005 86 : 405 412.
74. Chu JJ, Ng ML. Interaction of West Nile virus with alpha v beta 3 integrin mediates virus entry into cells. J Biol Chem 2004 279 : 54533 54541.
75. Lee JW, Chu JJ, Ng ML. Quantifying the specific binding between West Nile virus envelope domain III protein and the cellular receptor alphaVbeta3 integrin. J Biol Chem 2006 281 : 1352 1360.
76. Davis CW, Nguyen HY, Hanna SL, Sanchez MD, Doms RW, Pierson TC. West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection. J Virol 2006 80 : 1290 1301.
77. Davis CW, Mattei LM, Nguyen HY, Doms RW, Pierson TC. The location of N-linked glycans on West Nile virions controls their interactions with CD209. J Biol Chem 2006 281 : 37183 37194.
78. Zhang Y, et al. Conformational changes of the flavivirus E glycoprotein. Structure (Camb) 2004 12 : 1607 1618.
79. Zhang W, et al. Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nat Struct Biol 2003 10 : 907 912.
80. Mukhopadhyay S, Kim BS, Chipman PR, Rossmann MG, Kuhn RJ. Structure of West Nile virus. Science 2003 302 : 248.
81. Zhang Y, Kaufmann B, Chipman PR, Kuhn RJ, Rossmann MG. Structure of immature West Nile virus. J Virol 2007 81 : 6141 6145.
82. Heinz F, et al. Structural changes and functional control of the tick-borne encephalitis virus glycoprotein E by the heterodimeric association with the protein prM. Virology 1994 198 : 109 117.
83. Stadler K, Allison SL, Schalich J, Heinz FX. Proteolytic activation of tick-borne encephalitis virus by furin. J Virol 1997 71 : 8475 8481.
84. Colman PM, Lawrence MC. The structural biology of type I viral membrane fusion. Nat Rev Mol Cell Biol 2003 4 : 309 319.
85. Colombage G, Hall R, Pavy M, Lobigs M. DNA-based and alphavirus-vectored immunisation with prM and E proteins elicits long-lived and protective immunity against the flavivirus, Murray Valley encephalitis virus. Virology 1998 250 : 151 163.
86. Pincus S, et al. Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis. Virology 1992 187 : 290 297.
87. Falconar AK. Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins. Arch Virol 1999 144 : 2313 2330.
88. Vazquez S, et al. Immune response to synthetic peptides of dengue prM protein. Vaccine 2002 20 : 1823 1830.
89. Chung KM, Thompson BS, Fremont DH, Diamond MS. Antibody recognition of cell surface-associated NS1 triggers Fc-g receptor mediated phagocytosis and clearance of WNV infected cells. J Virol 2007 81 : 9551 9555.
90. Wong SJ, et al. Immunoassay targeting nonstructural protein 5 to differentiate West Nile virus infection from dengue and St. Louis encephalitis virus infections and from flavivirus vaccination. J Clin Microbiol 2003 41 : 4217 4223.
91. Kimura-Kuroda J, Yasui K. Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies. J Immunol 1988 141 : 3606 3610.
92. Roehrig JT, Staudinger LA, Hunt AR, Mathews JH, Blair CD. Antibody prophylaxis and therapy for flaviviral encephalitis infections. Ann NY Acad Sci 2001 951 : 286 297.
93. Schlesinger JJ, Walsh EE, Brandriss MW. Analysis of 17D yellow fever virus envelope protein epitopes using monoclonal antibodies. J Gen Virol 1984 65 : 1637 1644.
94. Roehrig JT, Mathews JH, Trent DW. Identification of epitopes on the E glycoprotein of Saint Louis encephalitis virus using monoclonal antibodies. Virology 1983 128 : 118 126.
95. Mathews JH, Roehrig JT. Elucidation of the topography and determination of the protective epitopes on the E glycoprotein of Saint Louis encephalitis virus by passive transfer with monoclonal antibodies. J Immunol 1984 132 : 1533 1537.
96. Beasley DW, Barrett AD. Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J Virol 2002 76 : 13097 13100.
97. Sanchez MD, et al. Characterization of neutralizing antibodies to West Nile virus. Virology 2005 336 : 70 82.
98. Oliphant T, et al. The induction of epitope-specific neutralizing antibodies against West Nile virus. J Virol 2007 81 : 11828 11839.
99. Sanchez MD, et al. The neutralizing antibody response against West Nile virus in naturally infected horses. Virology 2007 359 : 336 348.
100. Sitati E, Diamond MS. CD4+ T cell responses are required for clearance of West Nile Virus from the central nervous system. J Virol 2006 80 : 12060 12069.
101. Sitati E, McCandless EE, Klein RS, Diamond MS. CD40-CD40 ligand interactions promote trafficking of CD8+ T cells into the brain and protection against West Nile virus encephalitis. J Virol 2007 81 : 9801 9811.
102. Oliphant T, Diamond MS. The molecular basis of antibody-mediated neutralization of West Nile virus. Expert Opin Biol Ther 2007 7 : 885 892.
103. Nybakken G, Oliphant T, Johnson S, Burke S, Diamond MS, Fremont DH. Structural basis for neutralization of a therapeutic antibody against West Nile virus. Nature 2005 437 : 764 769.
104. Choi KS, Nah JJ, Ko YJ, Kim YJ, Joo YS. The DE loop of the domain III of the envelope protein appears to be associated with West Nile virus neutralization. Virus Res 2007 123 : 216 218.
105. Crill WD, Chang GJ. Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol 2004 78 : 13975 13986.
106. Crill WD, Trainor NB, Chang GJ. A detailed mutagenesis study of flavivirus cross-reactive epitopes using West Nile virus-like particles. J Gen Virol 2007 88 : 1169 1174.
107. Stiasny K, Kiermayr S, Holzmann H, Heinz FX. Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J Virol 2006 80 : 9557 9568.
108. Goncalvez AP, Purcell RH, Lai CJ. Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein. J Virol 2004 78 : 12919 12928.
109. Daffis S, Kontermann RE, Korimbocus J, Zeller H, Klenk HD, Ter Meulen J. Antibody responses against wild-type yellow fever virus and the 17D vaccine strain: characterization with human monoclonal antibody fragments and neutralization escape variants. Virology 2005 337 : 262 272.
110. Ryman KD, Ledger TN, Weir RC, Schlesinger JJ, Barrett AD. Yellow fever virus envelope protein has two discrete type-specific neutralizing epitopes. J Gen Virol 1997 78 : 1353 1356.
111. Lai CJ, et al. Epitope determinants of a chimpanzee dengue virus type 4 (DENV-4)-neutralizing antibody and protection against DENV-4 challenge in mice and rhesus monkeys by passively transferred humanized antibody. J Virol 2007 81 : 12766 12774.
112. Pierson TC, et al. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 2007 1 : 135 145.
113. Burton DR, Saphire EO, Parren PW. A model for neutralization of viruses based on antibody coating of the virion surface. Curr Top Microbiol Immunol 2001 260 : 109 143.
114. Klasse PJ, Burton DR. Antibodies to West Nile virus: a double-edged sword. Cell Host Microbe 2007 1 : 87 89.
115. Klasse PJ, Sattentau QJ. Mechanisms of virus neutralization by antibody. Curr Top Microbiol Immunol 2001 260 : 87 108.
116. Klasse PJ, Sattentau QJ. Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J Gen Virol 2002 83 : 2091 2108.
117. Kauffman B, et al. West Nile virus in complex with a neutralizing monoclonal antibody. Proc Natl Acad Sci USA 2006 103 : 12400 12404.
118. Mandl CW, Allison SL, Holzmann H, Meixner T, Heinz FX. Attenuation of tick-borne encephalitis virus by structure-based site-specific mutagenesis of a putative flavivirus receptor binding site. J Virol 2000 74 : 9601 9609.
119. Holzmann H, Heinz FX, Mandl CW, Guirakhoo F, Kunz C. A single amino acid substitution in envelope protein E of tick-borne encephalitis virus leads to attenuation in the mouse model. J Virol 1990 64 : 5156 5159.
120. Se-Thoe SY, Ling AE, Ng MM. Alteration of virus entry mode: a neutralisation mechanism for Dengue-2 virus. J Med Virol 2000 62 : 364 376.
121. Gollins SW, Porterfield JS. A new mechanism for the neutralization of enveloped viruses by antiviral antibody. Nature 1986 321 : 244 246.
122. Peiris JS, Porterfield JS. Antibody-mediated enhancement of Flavivirus replication in macrophage-like cell lines. Nature 1979 282 : 509 511.
123. Peiris JSM, Gordon S, Unkeless JC, Porterfield JS. Monoclonal anti-Fc receptor IgG blocks antibody-dependent enhancement of viral replication in macrophages. Nature 1981 289 : 189 191.
124. Halstead SB. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J Infect Dis 1979 140 : 527 533.
125. Halstead SB. Observations related to pathogensis of dengue hemorrhagic fever. VI. Hypotheses and discussion. Yale J Biol Med 1970 42 : 350 362.
126. Mehlhop E, et al. Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host Microbe 2007 2 : 417 426.
127. Yamanaka A, Kosugi S, Konishi E. Infection-enhancing and -neutralizing activities of mouse monoclonal antibodies against dengue type 2 and 4 viruses are controlled by complement levels. J Virol 2008 82 : 927 937.
128. Ravetch JV, Kinet JP. Fc receptors. Annu Rev Immunol 1991 9 : 457 492.
129. Shresta S, Sharar KL, Prigozhin DM, Beatty PR, Harris E. Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol 2006 80 : 10208 10217.
130. Hamdan A, Green P, Mendelson E, Kramer MR, Pitlik S, Weinberger M. Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitis. Transpl Infect Dis 2002 4 : 160 162.
131. Shimoni Z, Niven MJ, Pitlick S, Bulvik S. Treatment of West Nile virus encephalitis with intravenous immunoglobulin. Emerg Infect Dis 2001 7 : 759.
132. Morrey JD, et al. Defining limits of humanized neutralizing monoclonal antibody treatment for West Nile virus neurological infection in a hamster model. Antimicrob Agents Chemother 2007 51 : 2396 2402.
133. Berry DM, Almeida JD. The morphological and biological effects of various antisera on avian infectious bronchitis virus. J Gen Virol 1968 3 : 97 102.
134. Cooper NR, Jensen FC, Welsh RM Jr., Oldstone MB. Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway. J Exp Med 1976 144 : 970 984.
135. Jayasekera JP, Moseman EA, Carroll MC. Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity. J Virol 2007 81 : 3487 3494.
136. Hessell AJ, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007 449 : 101 104.
137. Kishore U, Reid KB. C1q: structure, function, and receptors. Immunopharmacology 2000 49 : 159 170.
138. Barnes N, Gavin AL, Tan PS, Mottram P, Koentgen F, Hogarth PM. FcgammaRI-deficient mice show multiple alterations to inflammatory and immune responses. Immunity 2002 16 : 379 389.
139. Pierson TC, Diamond MS. Molecular mechanisms of antibody-mediated neutralization of flavivirus infection. Exp Rev Mol Med 2008 10 : e12.